Dan Skovronsky knows what makes good obesity medicines.
As Chief Science Officer of Eli Lilyhe’s already done it once with a weekly shot of the company, Zepbound. He’s trying to do it again with a more convenient daily pill. And repeat the feat with a shot that is even stronger than Zepbound. And it doesn’t count tests in clinical trials for the other nine obesity drug Lily.
Skovronsky said the race to create the next great drug is not just weight loss, but more investors and analysts are beginning to say.
take amgenThe experimental drug of maritide: lost up to 20% of body weight in a phase 2 study, and the Amgen strain fell by about 5% on the day it was announced in November. why? Investors were worried that it would not be enough to compete with Lily’s Zepbound and Novo Nordisk’s Wegoby.
Eli Lilly & Co was placed in the Brooklyn Borough of New York, USA on Thursday, March 28th, 2024. Zepbound injection pen.
Shelby Knowles | Bloomberg | Getty Images
Skovornsky sees it as two pathways to improve ease of use, create more powerful drugs, and advance the field. He expects drugs like Lily’s Orforglipron to reach people all over the world. He sees drugs that can lead to more weight loss as a potential area, including Lily’s own lettutortide.
But he is most excited to see the other health conditions the medication can treat: how many health conditions the intestinal hormones have. Lily’s Zepbound was recently approved to treat sleep apnea. The company is also investigating whether it can treat addiction, heart disease, inflammation and gastrointestinal conditions.
For more information about Lily’s obesity work and where the market progresses, you can see the full interview.
